|
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study …
PR Newswire (press release) Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. |
View full post on asthma – Google News